Background: Nonalcoholic fatty liver disease (NAFLD), defined as excessive liver fat deposition and one of end-stage liver disease causes. Increased ferritin levels are associated with insulin resistance and a higher hepatic iron and fat content. Hyperferritinemia has been associated with severity of liver damage in NAFLD. The study aimed to evaluate the effects of phlebotomy on liver enzymes and histology in such patients. Materials and Methods: Thirty-two eligible patients who had NAFLD and after 6 months of lifestyle modification still had NAFLD, and whose ferritin serum was above 250 mg/dl, were enrolled in this clinical trial study. After written informed consent was obtained, each patient's blood serum was taken for aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALK-P), complete blood count (CBC), total iron-binding capacity (TIBC), iron, and ferritin. Then the patients underwent liver biopsy. After that patients underwent phlebotomy, giving 350 cc blood monthly. Before every phlebotomy, hemoglobin and ferritin were checked. If they were in the goal range, phlebotomy was discontinued and the patient underwent liver biopsy. A serum sample was taken for testing at the beginning of the study. The results before and after phlebotomy were compared. The maximum duration of the study was 6 months. Results: Thirty-two patients (26 males and 6 females) were enrolled, and the mean average age was 33.7 ± 6.74 years. Phlebotomy improved liver enzymes and histology of liver significantly (P < 0.001) and induced reduction of ferritin. Conclusion: Phlebotomy is effective for the improvement of liver enzymes and histology in patients with NAFLD and hyperferritinemia.
Introduction
Nonalcoholic fatty liver disease (NAFLD) encompasses the accumulation of triglycerides in the cytoplasm of hepatocytes in the rate of 5-10% weight in the absence of liver disease, alcohol consumption, and other diseases.
[1] The pathogenesis of the disease is unclear but may be the result of several factors, including insulin resistance, oxidative stress dyslipidemia, abdominal obesity, diabetes, hypertension, and some additional factors. [1, 2] NAFLD is the most common liver disease and its prevalence in the general population is 20-30%.
[2] It is considered a hepatic manifestation of metabolic syndrome and includes a wide range of diseases from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis.
[3] In fact, 20% of those with NASH may evolve to cirrhosis during their lifetimes and it is the third leading cause of liver transplants in the world.
[4] Therefore, the diagnosis and treatment of NASH and [2] A diagnosis of NAFLD requires confirmation of hepatic steatosis based on imaging, biochemical studies, and liver biopsy. Most patients with NAFLD are asymptomatic and it is detected during routine checkup or other imaging for other conditions such as gallbladder problems, but there are some clinical symptoms that are nonspecific and include fatigue and malaise, abdominal discomfort, pain in the right upper quadrant, nausea, and other symptoms.
Effects of Phlebotomy on Liver Enzymes and Histology of Patients with Nonalcoholic Fatty Liver Disease
[3] Although the pathogenesis of this disease is still poorly understood, two hypotheses has been expressed. The first hypothesis involves triglyceride accumulation in the liver, causing steatosis, and the second hypothesis involves inflammation, oxidative stress, and inflammatory cytokines causing damage to liver cells. [2] [3] [4] Currently there is no effective full treatment for NAFLD; weight loss and
